CAL-130 is a potent and selective PI3K gamma and delta inhibitor with potential anticancer activity. Constitutive phosphoinositide 3-kinase (PI3K)/Akt activation is common in T cell acute lymphoblastic leukemia (T-ALL). Although four distinct class I PI3K isoforms (α, β, γ, δ) could participate in T-ALL pathogenesis, none has been implicated in this process. In the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed tumor formation. 苏州蚂蚁淘代理MedKoo在中国的业务。 MedKoo北京代理，MedKoo华东代理，MedKoo华北代理，MedKoo华中代理，MedKoo华南代理,MedKoo全国代理。 MedKoo公司是2009年由Qingqi Chen博士创立。在美国北卡罗来纳州的三角研究园区有运营办公室，其研发和生产车间位于中国。陈博士在加入MedKoo之前，是中山大学药学院（中山大学，中国广州）和中国科学院（北京）“100人计划”的杰出教授。对小分子抗癌药物有浓厚兴趣，发表了100多篇论文，获得20多项。Medkoo是处于先进地位的小分子抗癌试剂，激酶抑制剂和其他相关化学品的优秀供应商。 MedKoo部分产品列表：MedKoo全国代理 406757 10058-F4 530576 10074-G5 600110 10-Deacetylbaccatin III 530429 10-Gingerol 406281 10-Hydroxycamptothecin 341231 10-Hydroxyyohimbine 571387 [11C]-ABP688 526406 11-deoxy-PGF2a 525629 123C4   561223 12-Crown-4 featured 525697 1,3,5,6-Tetrahydroxyxanthone 526087 1,3,5-Trihydroxyxanthone 584120 1,3,7-Trimethyluric acid 527871 1,3-Dicaffeoylquinic acid 530605 1400W HCl